SNCA and neuroblastoma: In 2021, Izco et al. assessed the half-life of α-syn in a neuroblastoma cell line, genetically modified to overexpress wild-type full-length human alpha synuclein (WT α-syn SH-SY5Y), using a standard cycloheximide method.